Pharm-Olam is now Allucent. Learn More
Sponsor Testimonial
Biotech - Director ClinOps
Our Vaccines Development experts have extensive experience designing, implementing, and executing clinical trials involving live attenuated, inactivated, subunit, toxoid, mRNA, and viral vector vaccines for infectious diseases, allergies, immunotherapies, and oncology indications including; COVID-19, Hepatitis B & C, grass, birch, and dust mite allergies, cervical cancer and melanoma.
Data-driven, risk-based monitoring solutions, including centralized monitoring, designed specifically to take into account large data volume upon enrolment of vaccine trials, whilst ensuring data integrity in remote settings.
Natural selection of pathogens, diversity of trial participants, and timing are all important site selection criteria for infectious disease clinical trials. Our global reach, including industry-leading Central & Eastern Europe specialization, provides access to patient populations, site networks, and academic institutions, focused on meeting and exceeding your enrolment goals.
Pharm-Olam's teams have deep expertise in supporting studies in an ICU/critical care setting and navigating the common challenges encountered in this complex environment. That knowledge enables us to provide proactive and insightful CRO services based on proven strategies for indications from Pneumonia to COVID-19 and everywhere in between.
We have supported federally-funded vaccine and infectious disease clinical research programs for more than 20 years. Our proven track record has allowed us to collaborate with multiple government agencies including NIH, DOD, BARDA, and CDC.
Whether your new product is a drug, vaccine, biologic, GMO, cell and gene therapy, device, or a combination product, we understand the nuances of regulatory requirements and have the resources and proven expertise to address your specific needs.
Pharm-Olam stands with the global community in the fight against COVID-19. No other disease in recent history has captured the world like Coronavirus. As a Vaccine and Infectious Disease CRO, we are poised to help pharmaceutical and biotech’s by rapidly deploying their clinical trials in the search for vaccines and therapies to fight infectious disease. Together, we can create a healthier world.
We have several ongoing COVID-19 studies and are proud to have been selected by the US Department of Defense as a prime CRO contractor in support of Operation Warp Speed and continue these efforts through ongoing activities in support of its successor, the Countermeasures Acceleration Group (CAG).
We understand that drug development partners with medical countermeasures (MCM) expertise are crucial in bringing vaccines and treatments to the front lines of the COVID-19 battle. As an MCM-capable CRO, Pharm-Olam is ready to go the distance.
We can help! Pharm-Olam currently holds memberships in the Medical CBRN Defense Consortium (MCDC). We also work with the DoD's Other Transaction Authority (OTA) and under Other Transactions (OTs).
The impact respiratory viral infections have on the health and well-being of the world’s populations has been brought to the forefront with the ongoing COVID-19 pandemic. In this article, Dr. Kelly McKee discusses recent progress and innovations within RSV research.
Learn More
Pharm-Olam has supported over 75 infectious disease and vaccine clinical trials including 14 product approvals. Download the fact sheet to learn more about our global reach and expertise in Infectious Disease and Vaccine Clinical Research.
Download Now
Pharm-Olam provided a complete enrollment solution for the management and data submission of this Acute Bacterial Skin and Skin Structure Infection Study.
Read Case Study